TG Shifts Focus To MS After Pausing Oncology Programs, Ukoniq Withdrawal
Company Looks Ahead To Ublituximab PDUFA Date
TG Therapeutics is withdrawing the PI3K-delta inhibitor from the market and halting enrolling in other umbralisib oncology studies to focus attention on ublituximab in relapsing multiple sclerosis.
